Company intelligence / Profile preview

EurekaBio

Shenzhen, Guangdong, Chinaeurekabio.com ↗

Ownership: Private
Development stage: Other

Overview

EurekaBio has commercialized the EuLV™ Lentiviral Vector Production System, which enables high-titer, stable lentiviral vector production using stable cell lines in serum-free suspension. This system is designed to improve consistency, reduce costs, and streamline large-scale manufacturing of viral vectors critical for cell and gene therapies. The company also offers automated solutions covering the full spectrum of cell therapy manufacturing processes[1][6].

Therapeutic areas: Oncology
Modalities: Lentiviral vector (as a platform for gene delivery)Cell therapy (enabling technology)
Industry: Non-Drug Biotech

Partnerships

Collaborations with leading CAR-T companies in ChinaPartnerships with research institutions and pharmaceutical companies focused on CGT

Beyond the preview

Go deeper on EurekaBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EurekaBio.

Explore the full profile